Virax Biolabs Group Limited (VRAX)
 NASDAQ: VRAX · Real-Time Price · USD
 0.5620
 -0.0310 (-5.23%)
  At close: Oct 31, 2025, 4:00 PM EDT
0.5600
 -0.0020 (-0.36%)
  After-hours: Oct 31, 2025, 7:13 PM EDT
Virax Biolabs Group Revenue
In the fiscal year ending March 31, 2025, Virax Biolabs Group had annual revenue of $6.33K, down -95.95%. Virax Biolabs Group had revenue of $1.38K in the half year ending March 31, 2025, a decrease of -50.80%.
Revenue (ttm) 
 $6.33K
Revenue Growth 
 -95.95%
P/S Ratio 
 396.82
Revenue / Employee 
 $333
Employees 
 19
Market Cap 
2.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Mar 31, 2025 | 6.33K | -150.09K | -95.95% | 
| Mar 31, 2024 | 156.42K | 147.86K | 1,727.11% | 
| Mar 31, 2023 | 8.56K | - | - | 
| Mar 31, 2022 | - | - | - | 
| Mar 31, 2021 | 123.82K | 23.94K | 23.97% | 
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
VRAX News
- 2 months ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire
- 3 months ago - Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy - PRNewsWire
- 3 months ago - Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - PRNewsWire
- 7 months ago - Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga
- 8 months ago - Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes - PRNewsWire
- 8 months ago - Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting - PRNewsWire
- 8 months ago - Virax Biolabs to Present at 19th World Immune Regulation Meeting - PRNewsWire
- 8 months ago - Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy - PRNewsWire